• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖相关性射血分数保留型心力衰竭:诊断和治疗挑战。

Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges.

机构信息

Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

Korean J Intern Med. 2023 Mar;38(2):157-166. doi: 10.3904/kjim.2022.271. Epub 2023 Feb 6.

DOI:10.3904/kjim.2022.271
PMID:36740840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9993108/
Abstract

The prevalence of heart failure with preserved ejection fraction (HFpEF) has increased in recent decades. In particular, obesity-related HFpEF is a distinct and frequently encountered phenotype; however, its diagnosis is complex. Furthermore, the management of obesity-related HFpEF has not been established despite the introduction of promising drugs. This review summarizes the diagnostic challenges, pathophysiology, and therapeutic options for obesity-related HFpEF.

摘要

近年来,射血分数保留的心力衰竭(HFpEF)的患病率有所增加。特别是,肥胖相关性 HFpEF 是一种独特且常见的表型;然而,其诊断较为复杂。此外,尽管出现了有前途的药物,但肥胖相关性 HFpEF 的治疗方法尚未确定。本文总结了肥胖相关性 HFpEF 的诊断挑战、病理生理学和治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f2e/9993108/3172b3d874ea/kjim-2022-271f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f2e/9993108/344804e451b6/kjim-2022-271f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f2e/9993108/758596d6cf63/kjim-2022-271f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f2e/9993108/841214da65ef/kjim-2022-271f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f2e/9993108/3172b3d874ea/kjim-2022-271f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f2e/9993108/344804e451b6/kjim-2022-271f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f2e/9993108/758596d6cf63/kjim-2022-271f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f2e/9993108/841214da65ef/kjim-2022-271f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f2e/9993108/3172b3d874ea/kjim-2022-271f4.jpg

相似文献

1
Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges.肥胖相关性射血分数保留型心力衰竭:诊断和治疗挑战。
Korean J Intern Med. 2023 Mar;38(2):157-166. doi: 10.3904/kjim.2022.271. Epub 2023 Feb 6.
2
Obesity-Related Heart Failure with Preserved Ejection Fraction: Pathophysiology, Diagnosis, and Potential Therapies.肥胖相关性射血分数保留的心力衰竭:病理生理学、诊断和潜在治疗方法。
Heart Fail Clin. 2020 Jul;16(3):357-368. doi: 10.1016/j.hfc.2020.02.004.
3
Diagnostic and therapeutic challenges for PCPs regarding heart failure with preserved ejection fraction and obesity: results of an online internet-based survey.基层医疗医生在射血分数保留的心力衰竭和肥胖方面面临的诊断与治疗挑战:一项基于网络的在线调查结果
BMC Prim Care. 2024 Aug 8;25(1):288. doi: 10.1186/s12875-024-02549-4.
4
Obesity and heart failure with preserved ejection fraction: A growing problem.肥胖与射血分数保留的心力衰竭:日益严重的问题。
Trends Cardiovasc Med. 2018 Jul;28(5):322-327. doi: 10.1016/j.tcm.2017.12.003. Epub 2017 Dec 14.
5
Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction.支持射血分数保留的心力衰竭存在独特肥胖表型的证据。
Circulation. 2017 Jul 4;136(1):6-19. doi: 10.1161/CIRCULATIONAHA.116.026807. Epub 2017 Apr 5.
6
Obesity and Heart Failure with Preserved Ejection Fraction.肥胖与射血分数保留的心力衰竭。
Heart Fail Clin. 2021 Jul;17(3):345-356. doi: 10.1016/j.hfc.2021.02.003.
7
Heart failure with preserved ejection fraction: everything the clinician needs to know.射血分数保留的心力衰竭:临床医生需要了解的一切。
Lancet. 2024 Mar 16;403(10431):1083-1092. doi: 10.1016/S0140-6736(23)02756-3. Epub 2024 Feb 14.
8
Heart Failure With Preserved Ejection Fraction.射血分数保留的心力衰竭
Curr Probl Cardiol. 2016 Apr;41(4):145-88. doi: 10.1016/j.cpcardiol.2015.12.002. Epub 2015 Dec 9.
9
[Heart failure with preserved ejection fraction (HFpEF)].射血分数保留的心力衰竭(HFpEF)
Ther Umsch. 2018 Sep;75(3):161-169. doi: 10.1024/0040-5930/a000983.
10
Heart failure with preserved ejection fraction.射血分数保留的心力衰竭
Circ J. 2009 Mar;73(3):404-10. doi: 10.1253/circj.cj-08-1073. Epub 2009 Feb 4.

引用本文的文献

1
Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies.射血分数保留的心力衰竭与肥胖:新兴的代谢治疗策略
Diabetol Metab Syndr. 2025 Aug 18;17(1):336. doi: 10.1186/s13098-025-01917-z.
2
Exercise Hemodynamics and Sex-Specific Data in Asymptomatic Adults: An Exploratory Pilot Study.无症状成年人的运动血流动力学和性别特异性数据:一项探索性初步研究。
Diagnostics (Basel). 2025 May 23;15(11):1307. doi: 10.3390/diagnostics15111307.
3
Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatment.

本文引用的文献

1
Heart Failure Statistics in Korea, 2020: A Report from the Korean Society of Heart Failure.《2020年韩国心力衰竭统计数据:来自韩国心力衰竭学会的报告》
Int J Heart Fail. 2021 Sep 8;3(4):224-236. doi: 10.36628/ijhf.2021.0023. eCollection 2021 Oct.
2
Sex-related differences among young adults with heart failure: Does sex matter?年轻心力衰竭患者的性别差异:性别有影响吗?
Int J Cardiol. 2022 Oct 1;364:91-92. doi: 10.1016/j.ijcard.2022.05.062. Epub 2022 Jun 1.
3
Gliflozins in the Management of Cardiovascular Disease.格列净类药物在心血管疾病管理中的应用
肥胖与射血分数保留的心力衰竭:聚焦于新药及药物治疗的未来方向
Korean J Intern Med. 2025 May;40(3):357-370. doi: 10.3904/kjim.2024.387. Epub 2025 Apr 30.
4
Addressing Cardiovascular Diseases Challenges in South Korea: Strategies to Improve Outcomes.应对韩国心血管疾病挑战:改善治疗效果的策略
Korean Circ J. 2025 Jul;55(7):557-583. doi: 10.4070/kcj.2024.0385. Epub 2025 Apr 7.
5
Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review.射血分数保留的心力衰竭的肥胖相关表型:一项综述
Cureus. 2025 Mar 31;17(3):e81512. doi: 10.7759/cureus.81512. eCollection 2025 Mar.
6
Diagnosing Heart Failure with Preserved Ejection Fraction in Obese Patients.诊断肥胖患者射血分数保留的心力衰竭
J Clin Med. 2025 Mar 14;14(6):1980. doi: 10.3390/jcm14061980.
7
Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction.超越体重减轻:胰高血糖素样肽-1受体激动剂治疗射血分数保留的心力衰竭的潜力
Heart Fail Rev. 2025 Jan;30(1):17-38. doi: 10.1007/s10741-024-10438-2. Epub 2024 Sep 13.
8
Cardiorespiratory Performance in Kidney and Liver Transplant Recipients: The Dilemma to Combine Lifestyle and Fitness.肾移植和肝移植受者的心肺功能:生活方式与健康状况相结合的困境
J Funct Morphol Kinesiol. 2024 Feb 29;9(1):44. doi: 10.3390/jfmk9010044.
9
Obesity-related hypertension and chronic kidney disease: from evaluation to management.肥胖相关高血压与慢性肾脏病:从评估到管理
Kidney Res Clin Pract. 2023 Jul;42(4):431-444. doi: 10.23876/j.krcp.23.072. Epub 2023 Jul 14.
N Engl J Med. 2022 May 26;386(21):2024-2034. doi: 10.1056/NEJMra2115011.
4
HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction.HFA-PEFF 评分:在射血分数保留的心力衰竭中的预后价值。
Korean J Intern Med. 2022 Jan;37(1):96-108. doi: 10.3904/kjim.2021.272. Epub 2021 Dec 21.
5
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.钠-葡萄糖协同转运蛋白 2 抑制剂达格列净治疗射血分数保留的心力衰竭:一项多中心随机试验。
Nat Med. 2021 Nov;27(11):1954-1960. doi: 10.1038/s41591-021-01536-x. Epub 2021 Oct 28.
6
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
7
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
8
Performance of the HFPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: A report from the Japanese multicenter registry.HFPEF 和 HFA-PEFF 评分在日本心力衰竭保留射血分数患者诊断中的表现:来自日本多中心注册研究的报告。
Int J Cardiol. 2021 Nov 1;342:43-48. doi: 10.1016/j.ijcard.2021.08.001. Epub 2021 Aug 5.
9
Empagliflozin-Induced Changes in Epicardial Fat: The Centerpiece for Myocardial Protection?恩格列净引起的心外膜脂肪变化:心肌保护的核心因素?
JACC Heart Fail. 2021 Aug;9(8):590-593. doi: 10.1016/j.jchf.2021.05.006.
10
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.恩格列净在非糖尿病射血分数降低心衰患者中的作用机制:来自 EMPA-TROPISM 研究。
JACC Heart Fail. 2021 Aug;9(8):578-589. doi: 10.1016/j.jchf.2021.04.014.